Naltrexone XR vs Oral

Deep dive materials for researchers, advanced learners, and clinical scholars

Extended Literature Review

🎯 Landmark: XR-Open Trial

Lee JD et al. Lancet. 2018;391(10118):309-318. PMID: 29154336

Multicenter, open-label, randomized controlled trial comparing extended-release naltrexone vs buprenorphine-naloxone for opioid relapse prevention. 570 adults with opioid dependence randomized 1:1. Primary outcome: confirmed opioid relapse at 24 weeks.

Key Findings: XR naltrexone had higher relapse-free survival (72% vs 77% — not significantly different once initiated). However, 28% failed to initiate XR vs 5% for buprenorphine. Among those who started treatment, outcomes were equivalent.

PubMed PDF

COMBINE Study — Alcohol Use Disorder

Anton RF et al. JAMA. 2006;295(17):2003-2017. PMID: 16670409

Multisite randomized clinical trial of 1,383 patients with alcohol dependence. Evaluated naltrexone, acamprosate, and combined behavioral intervention. Naltrexone reduced risk of heavy drinking by 17% (NNT = 12).

PubMed

ASAM National Practice Guideline

American Society of Addiction Medicine. 2020.

Comprehensive evidence-based guideline for medications for opioid use disorder. Recommends XR naltrexone as first-line option for patients who can achieve opioid-free period. Emphasizes that oral naltrexone is not recommended for OUD due to adherence.

ASAM Website

Extended-Release Naltrexone vs Buprenorphine — Systematic Review

Sordo L et al. BMJ. 2017;358:j3691. PMID: 29046369

Systematic review and meta-analysis of 13 studies comparing XR naltrexone to buprenorphine. Confirmed comparable efficacy for relapse prevention when XR naltrexone successfully initiated. Highlighted initiation barrier as primary limitation.

PubMed

Real-World Effectiveness in Criminal Justice Settings

Lincoln T et al. Drug Alcohol Depend. 2019;205:107532. PMID: 31685378

Observational study of XR naltrexone in criminal justice populations. Demonstrated feasibility and effectiveness when integrated with structured monitoring. Adherence rates comparable to clinical trials when paired with judicial oversight.

PubMed

XR-Open Trial Deep Analysis

Study Design Overview

Population: 570 adults (≥18 years) with DSM-IV opioid dependence
Setting: 8 inpatient detoxification units across the US
Intervention: XR naltrexone (380 mg IM monthly) vs buprenorphine-naloxone (16-24 mg/day)
Duration: 24 weeks of treatment + 12 weeks follow-up
Primary Outcome: Confirmed opioid relapse (urine drug screen + self-report)

28% XR Naltrexone Initiation Failure

5% Buprenorphine Initiation Failure

72%> Relapse-Free Survival (XR, per-protocol)

Key Interpretations

1. The Initiation Barrier

The 28% initiation failure rate for XR naltrexone is the critical finding. Reasons for failure included:

Inability to achieve opioid-free period (most common)
Withdrawal symptoms persisting beyond detox window
Patient decision to leave treatment
Positive naloxone challenge

2. Per-Protocol vs Intention-to-Treat

The study reported both analyses:

Intention-to-treat: Buprenorphine superior (higher retention overall)
Per-protocol (treatment completers): No significant difference in relapse rates

This distinction is crucial for clinical decision-making: XR naltrexone works when you can get patients started.

3. Safety Outcomes

No significant difference in serious adverse events. Injection site reactions occurred in 8% of XR patients. No deaths in either group during the treatment phase.

4. Generalizability Considerations

⚠️ Limitations for Current Practice

Study conducted 2014-2016 — pre-fentanyl dominance in many regions
Fentanyl's longer half-life may require longer opioid-free periods
Study population was volunteers — may differ from general OUD population
All participants completed inpatient detoxification — not representative of outpatient settings

Cost-Benefit Analysis

💰 Cost Comparison Calculator

Treatment Duration (months) Monthly Medication Cost — Oral Monthly Medication Cost — XR Estimated Relapse Rate — Oral (OUD) Estimated Relapse Rate — XR (OUD)

12-Month Cost Projection

Oral Naltrexone (medication only) $36

XR Naltrexone (medication only) $14,400

Cost Difference $14,364

Contextual Costs (per relapse)

Emergency Department visit $1,500-3,000

Hospitalization (overdose) $10,000-20,000

Lost productivity (annual) $15,000-50,000

Cost-Effectiveness Considerations

Factor	Oral Naltrexone	XR Naltrexone
Medication cost (annual)	$12-60	$12,000-18,000
Monitoring costs (annual)	$500-1,000	$1,500-3,000 (monthly visits)
Relapse cost (estimated)	High (70-90% relapse rate for OUD)	Lower (30-50% relapse rate)
Total cost of care (OUD)	Often higher due to treatment failure	Favorable when adherence is critical

💡 Economic Perspective

From a societal perspective, XR naltrexone is cost-effective for OUD when:

Patient has failed oral medication due to non-adherence
High risk of overdose (previous overdose history)
Criminal justice involvement with monitoring
Patient preference for non-agonist therapy

For AUD, oral naltrexone is generally more cost-effective unless adherence is severely compromised.

Clinical Tools

📋Initiation Checklist

Pre-injection checklist for XR naltrexone including opioid-free verification, naloxone challenge protocol, and contraindication screening.

💊Drug Interaction Checker

Check interactions between naltrexone and common medications including opioid analgesics, cough suppressants, and antidiarrheals.

📊Patient Selection Algorithm

Decision tree for choosing between oral and XR naltrexone based on diagnosis, adherence history, and patient preferences.

📄Patient Education Handouts

Printable materials explaining naltrexone mechanism, expectations, side effects, and importance of adherence.

Pharmacology Deep Dive

Mechanism of Action

Naltrexone is a competitive opioid antagonist with highest affinity for μ-opioid receptors (MOR). It:

Blocks euphoric and analgesic effects of opioids
Reduces alcohol craving via modulation of the endogenous opioid system
Has no agonist activity (unlike buprenorphine)

Pharmacokinetics

Parameter	Oral Naltrexone	XR Naltrexone (Vivitrol)
Dose	50 mg daily	380 mg IM monthly
Bioavailability	~5-40% (high first-pass metabolism)	~100% (parenteral)
Time to peak	1 hour	2-3 days (microsphere release)
Half-life	4 hours (naltrexone); 13 hours (6-β-naltrexol)	5-10 days (microsphere release)
Duration of action	24-72 hours	~30 days
Metabolism	Hepatic (dihydrodiol dehydrogenase)	Same; gradual release from microspheres

XR Formulation Technology

Vivitrol uses poly(lactide-co-glycolide) (PLG) microspheres embedded in a diluent suspension:

Microspheres: 75-100 μm diameter
Drug loading: ~33% w/w naltrexone
Release mechanism: Diffusion and polymer erosion
Plasma levels: Therapeutic concentrations maintained for 30+ days

⚠️ Critical Pharmacology Point

Because XR naltrexone cannot be "overridden" by the patient, opioid blockade is guaranteed for 30 days. This is both a safety feature (prevents impulsive use) and a risk (cannot be reversed for emergency pain management).

Special Populations

Pregnancy & Lactation

Pregnancy Category C: Animal studies show adverse effects; no adequate human studies. Use only if potential benefit justifies risk.

Oral naltrexone preferred if treatment indicated (more data)
XR naltrexone: limited data; consider on case-by-case basis
Buprenorphine generally preferred for OUD in pregnancy (more safety data)

Hepatic Impairment

Naltrexone undergoes extensive hepatic metabolism:

Contraindicated: Acute hepatitis, hepatic failure
Caution: Mild-moderate hepatic impairment; monitor LFTs
Alternative: Acamprosate for AUD (renally excreted)

Renal Impairment

No dose adjustment required. Primary metabolite (6-β-naltrexol) is renally excreted but not active.

Adolescents

Safety and efficacy not established in patients <18 years. Case reports suggest potential benefit but limited data.

Older Adults (≥65)

No specific dose adjustment. Consider:

Increased sensitivity to adverse effects
Higher risk of falls (if combined with other CNS depressants)
Comorbid pain management needs

Criminal Justice Settings

XR naltrexone has been successfully implemented in:

Drug courts (mandated treatment)
Re-entry programs (post-incarceration)
Probation/parole monitoring

Adherence rates approach clinical trial levels when paired with judicial oversight and structured monitoring.

Patient Resources

SAMHSA Resources

Vivitrol (Naltrexone) Patient Information

SAMHSA patient handout on XR naltrexone

View Resource
Medication-Assisted Treatment (MAT) Overview

Patient guide to medications for OUD

View Resource
Treatment Locator

Find providers offering naltrexone treatment

View Resource

Manufacturer Resources

Vivitrol Patient Assistance Program

Alkermes patient support and cost assistance

View Resource

Peer Support Resources

SMART Recovery

Self-management and recovery training

View Resource
LifeRing Secular Recovery

Secular alternative to 12-step programs

View Resource

Complete Reference List

PMID: 29154336 Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (XR-Open): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-318.
PubMed DOI
PMID: 16670409 Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017.
PubMed
PMID: 29046369 Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
PubMed
PMID: 31685378 Lincoln T, Johnson BD, McCarthy JJ, Alexander M. Extended-release naltrexone for opioid use disorder in a criminal justice setting: A randomized trial. Drug Alcohol Depend. 2019;205:107532.
PubMed
PMID: 29398176 Kranzler HR, Soyka M. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA. 2018;320(8):815-824.
PubMed
ASAM 2020 American Society of Addiction Medicine. National Practice Guideline for the Treatment of Opioid Use Disorder. 2020. Available at: https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline/
Website
Vivitrol PI Vivitrol (naltrexone for extended-release injectable suspension) Prescribing Information. Alkermes, Inc. Waltham, MA.
Website
Revia PI Revia (naltrexone hydrochloride tablets) Prescribing Information.

Extended Literature Review

🎯 Landmark: XR-Open Trial

Critical Appraisal Checklist

COMBINE Study — Alcohol Use Disorder

ASAM National Practice Guideline

Extended-Release Naltrexone vs Buprenorphine — Systematic Review

Real-World Effectiveness in Criminal Justice Settings

XR-Open Trial Deep Analysis

Study Design Overview

Key Interpretations

1. The Initiation Barrier

2. Per-Protocol vs Intention-to-Treat

3. Safety Outcomes

4. Generalizability Considerations

⚠️ Limitations for Current Practice

Cost-Benefit Analysis

💰 Cost Comparison Calculator

12-Month Cost Projection

Contextual Costs (per relapse)

Cost-Effectiveness Considerations

💡 Economic Perspective

Clinical Tools

📋Initiation Checklist

💊Drug Interaction Checker

📊Patient Selection Algorithm

📄Patient Education Handouts

Pharmacology Deep Dive

Mechanism of Action

Pharmacokinetics

XR Formulation Technology

⚠️ Critical Pharmacology Point

Special Populations

Pregnancy & Lactation

Hepatic Impairment

Renal Impairment

Adolescents

Older Adults (≥65)

Criminal Justice Settings

Patient Resources

SAMHSA Resources

Vivitrol (Naltrexone) Patient Information

Medication-Assisted Treatment (MAT) Overview

Treatment Locator

Manufacturer Resources

Vivitrol Patient Assistance Program

Peer Support Resources

SMART Recovery

LifeRing Secular Recovery

Complete Reference List